Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: The Japanese musculoskeletal oncology group cooperative study

Cancer

Volumn 109, Issue 4, 2007, Pages 767-775

  Obata, Hideto ^a   Ueda, Takafumi ^a,j   Kawai, Akira ^b   Ishii, Takeshi ^c   Ozaki, Toshifumi ^d   Abe, Satoshi ^e   Tanaka, Kazuhiro ^f   Tsuchiya, Hiroyuki ^g   Matsumine, Akihiko ^h   Yabe, Hiroo ⁱ  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c CHIBA CANCER CENTER   (Japan)

^d OKAYAMA UNIVERSITY   (Japan)

^e TEIKYO UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g KANAZAWA UNIVERSITY   (Japan)

^h MIE UNIVERSITY   (Japan)

ⁱ KEIO UNIVERSITY   (Japan)

^j OSAKA NATIONAL HOSPITAL   (Japan)

more..

Author keywords

Asian Continental Ancestry Group; Ewing; Sarcoma; Treatment outcome

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; EWING SARCOMA; FAMILIAL CANCER; FOLLOW UP; HUMAN; JAPAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; INFANT; INFANT, NEWBORN; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA, EWING'S; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33846921311     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22481     Document Type: Article

References (41)

1. Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer. 1993;53:371-376.
2. Wei G, Wanpeng X, Huvos AG, Healey JH, Chuanhan F. Comparative frequency of bone sarcomas among different racial groups. Chin Med J. 1999;112:1101-1104.
3. Stiller CA, Bunch KJ, Lewis IJ. Ethnic group and survival from childhood cancer: report from the UK Children's Cancer Study Group. Br J Cancer. 2000;82:1339-1343.
4. Wolf RE, Enneking WF. The staging and surgery of musculoskeletal neoplasms. Orthop Clin North Am. 1996;27:473-481.
5. Wexler LH, DeLaney TF, Tsokos M, et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 1996;78:901-911.
6. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694-701.
7. Granowetter L, Womer R, Devidas M. Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: a Pediatric Oncology Group-Children's Cancer Group Phase III trial. SIOP XXXIII meeting, Brisbane. Med Pediatr Oncol. 2001;37:172.
8. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol. 2003;21:3423-3430.
9. Rosito P, Mancini AF, Rondelli R, et al. Italian cooperative study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer. 1999;86:421-428.
10. Kimura K, Tatezaki S, Ishii T, Yonemoto T, Shigehara T, Takenouchi T. Hemiarthroplasty of the elbow with a vascularized fibular graft after excision of Ewing's sarcoma of the proximal ulna: a case report. Jpn J Clin Oncol. 2002;32:430-434.
11. Paulussen M, Ahrens S, Craft AW, et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol. 1998;16:3044-3052.
12. Rosen G, Juergens H, Caparros B, Nirenberg A, Huvos AG, Marcove RC. Combination chemotherapy (T-6) in the multidisciplinary treatment of Ewing's sarcoma. Natl Cancer Inst Monogr. 1981:289-299.
13. Rosen G. Current management of Ewing's sarcoma. Prog Clin Cancer. 1982;8:267-282.
14. Nesbit ME Jr, Perez CA, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup study. Natl Cancer Inst Monogr. 1981:255-262.
15. Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J Clin Oncol. 1990;8:1514-1524.
16. Jurgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European cooperative trial. Cancer. 1988;61:23-32.
17. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the Cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818-1829.
18. Tsuchiya H, Tomita K, Yamamoto N, Mori Y, Asada N. Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma. Anticancer Res. 1998;18(5B):3651-3656.
19. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12:1137-1149.
20. Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221-12230.
21. Uchida A, Isu K, Iwamoto Y, et al. General Rules for Clinical and Pathological Studies on Malignant Bone Tumors. 3rd ed. Tokyo: Kanehara & Company, Ltd.; 2000.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Craft A, Cotterill S, Malcolm A, et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol. 1998;16:3628-3633.
24. Paulussen M, Ahrens S, Braun-Munzinger G, et al. EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study) - preliminary results. Klin Padiatr. 1999;211:276-283.
25. Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol. 1999;17:180-190.
26. Elomaa I, Blomqvist CP, Saeter G, et al. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer. 2000;36:875-880.
27. Oberlin O, Deley MC, Bui BN, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646-1654.
28. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000;18:4-11.
29. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18:3108-3114.
30. Sauer R, Jurgens H, Burgers JM, Dunst J, Hawlicek R, Michaelis J. Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol. 1987;10:101-110.
31. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993;11:1763-1769.
32. Picci P, Bohling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997;15:1553-1559.
33. Shankar AG, Pinkerton CR, Atra A, et al. Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma.United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer. 1999;35:1698-1704.
34. Bacci G, Ferrari S, Longhi A, et al. Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Oncol Rep. 2004;11:111-120.
35. Schuck A, Ahrens S, Paulussen M, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003;55:168-177.
36. Meyer WH, Kun L, Marina N, et al. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J Clin Oncol. 1992;10:1737-42.
37. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol. 1993;11:1482-1488.
38. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998;9:275-281.
39. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005;23:4354-4362.
40. Horowitz ME, Kinselk TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993;11:1911-1918.
41. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol. 2001;19:2812-2820.